Etodolac-lidocaine Patch in Subjects Experiencing Acute Delayed Onset Muscle Soreness
Primary Purpose
Acute Delayed Onset Muscle Soreness (DOMS)
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Etodolac-lidocaine topical patch
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Acute Delayed Onset Muscle Soreness (DOMS)
Eligibility Criteria
Inclusion Criteria:
- Have not engaged in significant upper extremity fitness activities for more than two times per week for ≥ 2 consecutive weeks in the past 6 months prior to screening.
- Subject has a body mass index of between 18 and 30 kg/m2, inclusive.
- Subjects who report a pain with movement score in both arms of at least 5 (based on a 0-10 NRS) secondary to DOMS approximately 24 to 30 hours after each arm was exercised.
Exclusion Criteria:
- Presence of another painful physical condition that, in the opinion of the Investigator, may confound study assessments.
- Use of pain medication (including anti-inflammatory drugs) prior to the Exercise Visit until 72 hours after randomization.
- Use of any corticosteroids (oral, injectable, topical, inhaled) from before the Exercise Visit until randomization. Corticosteroids must be washed out by at least 3 days before the Exercise Visit.
- Chronic or acute renal or hepatic disorder, inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or a significant coagulation defect.
- History of allergy (cutaneous or systemic), asthma, hypersensitivity to any of the following: etodolac, lidocaine, paracetamol (acetaminophen), acetylsalicylic acid, salicylic acid, other NSAID, other local anesthetic, known intolerance (cutaneous or systemic) to any of the ingredients in the patch.
Sites / Locations
- Lotus Clinical Research
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Etodolac-lidocaine Topical Patch
Placebo
Arm Description
Therapy with experimental drug
Therapy with placebo
Outcomes
Primary Outcome Measures
Sum of the time-weighted differences from baseline in pain intensity with movement (SPIDMove) over 0-24 hours post-T0 (SPIDMove 0-24 hours).
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02695381
Brief Title
Etodolac-lidocaine Patch in Subjects Experiencing Acute Delayed Onset Muscle Soreness
Official Title
A Randomized, Double-blind, Multiple-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of Etodolac-lidocaine Patch Applied Once Daily in Subjects Experiencing Acute Delayed Onset Muscle Soreness
Study Type
Interventional
2. Study Status
Record Verification Date
September 2016
Overall Recruitment Status
Completed
Study Start Date
March 2016 (undefined)
Primary Completion Date
August 2016 (Actual)
Study Completion Date
September 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
MEDRx USA, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study evaluate the efficacy and safety of Etodolac-lidocaine topical patch applied one time daily when compared with placebo in the treatment of acute Delayed Onset Muscle Soreness (DOMS) of the upper limbs.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Delayed Onset Muscle Soreness (DOMS)
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Etodolac-lidocaine Topical Patch
Arm Type
Experimental
Arm Description
Therapy with experimental drug
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Therapy with placebo
Intervention Type
Drug
Intervention Name(s)
Etodolac-lidocaine topical patch
Other Intervention Name(s)
Etoreat
Intervention Description
Once daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Once daily
Primary Outcome Measure Information:
Title
Sum of the time-weighted differences from baseline in pain intensity with movement (SPIDMove) over 0-24 hours post-T0 (SPIDMove 0-24 hours).
Time Frame
24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Have not engaged in significant upper extremity fitness activities for more than two times per week for ≥ 2 consecutive weeks in the past 6 months prior to screening.
Subject has a body mass index of between 18 and 30 kg/m2, inclusive.
Subjects who report a pain with movement score in both arms of at least 5 (based on a 0-10 NRS) secondary to DOMS approximately 24 to 30 hours after each arm was exercised.
Exclusion Criteria:
Presence of another painful physical condition that, in the opinion of the Investigator, may confound study assessments.
Use of pain medication (including anti-inflammatory drugs) prior to the Exercise Visit until 72 hours after randomization.
Use of any corticosteroids (oral, injectable, topical, inhaled) from before the Exercise Visit until randomization. Corticosteroids must be washed out by at least 3 days before the Exercise Visit.
Chronic or acute renal or hepatic disorder, inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or a significant coagulation defect.
History of allergy (cutaneous or systemic), asthma, hypersensitivity to any of the following: etodolac, lidocaine, paracetamol (acetaminophen), acetylsalicylic acid, salicylic acid, other NSAID, other local anesthetic, known intolerance (cutaneous or systemic) to any of the ingredients in the patch.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paulette Saddler, MD
Organizational Affiliation
Lotus Clinical Research, LLC
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lotus Clinical Research
City
Pasadena
State/Province
California
ZIP/Postal Code
91195
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Etodolac-lidocaine Patch in Subjects Experiencing Acute Delayed Onset Muscle Soreness
We'll reach out to this number within 24 hrs